OncoSil Medical Ltd is an Australia-based company, which is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and bile duct cancer. OncoSil is a single-use brachytherapy (internal radiation) device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. OncoSil is comprised of Microparticles that contain a radioisotope and a specially formulated Diluent, which acts as a carrier to facilitate the implantation of the Microparticles into the target tissue. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The OncoSil System is supplied sterile and is intended for single-patient, single-use. OncoSil is approved in the various jurisdictions, including European Union, United Kingdom, Hong Kong, Singapore, Malaysia, New Zealand and Switzerland.